Terms: = Leukemia AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK
515 results:
1. Testing an Intervention to Improve Health Care Worker Well-Being During the COVID-19 Pandemic: A Cluster Randomized Clinical Trial.
Meredith LS; Ahluwalia S; Chen PG; Dong L; Farmer CM; Bouskill KE; Dalton S; Qureshi N; Blagg T; Timmins G; Schulson LB; Huilgol SS; Han B; Williamson S; Watson P; Schnurr PP; Martineau M; Davis K; Cassells A; Tobin JN; Gidengil C
JAMA Netw Open; 2024 Apr; 7(4):e244192. PubMed ID: 38687482
[TBL] [Abstract] [Full Text] [Related]
2. A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemia.
Ishida H; Kawahara Y; Tomizawa D; Okamoto Y; Hama A; Cho Y; Koh K; Koga Y; Yoshida N; Sato M; Terui K; Miyagawa N; Watanabe A; Takita J; Kobayashi R; Yamamoto M; Watanabe K; Okada K; Kato K; Matsumoto K; Hino M; Tabuchi K; Sakaguchi H
J Hematol Oncol; 2024 Apr; 17(1):24. PubMed ID: 38679709
[TBL] [Abstract] [Full Text] [Related]
3. Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
Zhao L; Yang J; Chen M; Xiang X; Ma H; Niu T; Gong Y; Chen X; Liu J; Wu Y
Ann Hematol; 2024 Apr; 103(4):1197-1209. PubMed ID: 38329487
[TBL] [Abstract] [Full Text] [Related]
4. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With
Russell NH; Wilhelm-Benartzi C; Othman J; Dillon R; Knapper S; Batten LM; Canham J; Hinson EL; Betteridge S; Overgaard UM; Gilkes A; Potter N; Mehta P; Kottaridis P; Cavenagh J; Hemmaway C; Arnold C; Freeman SD; Dennis M;
J Clin Oncol; 2024 Apr; 42(10):1158-1168. PubMed ID: 38215358
[TBL] [Abstract] [Full Text] [Related]
5. Iron Overload in Children With leukemia; Identification of a Cutoff Value for Serum Ferritin Level.
Zekavat OR; Fallah Tafti F; Bordbar M; Parand S; Haghpanah S
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e137-e142. PubMed ID: 38132565
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).
Ou SI; Hagopian GG; Zhang SS; Nagasaka M
J Thorac Oncol; 2024 May; 19(5):706-718. PubMed ID: 38070596
[TBL] [Abstract] [Full Text] [Related]
7. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
Jallouk AP; Kui N; Sun R; Westin JR; Steiner RE; Nair R; Nastoupil LJ; Fayad LE; Zaki AA; Hawkins M; Adkins S; Noorani M; Das K; Henderson J; Shpall EJ; Kebriaei P; Ramdial J; Flowers CR; Neelapu SS; Ahmed S; Strati P
Haematologica; 2024 May; 109(5):1460-1468. PubMed ID: 38031807
[TBL] [Abstract] [Full Text] [Related]
8. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract] [Full Text] [Related]
9. Cytogenetics in the management of mature T-cell and NK-cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Gaillard JB; Chapiro E; Daudignon A; Nadal N; Penther D; Chauzeix J; Nguyen-Khac F; Veronese L; Lefebvre C
Curr Res Transl Med; 2023; 71(4):103428. PubMed ID: 38016421
[TBL] [Abstract] [Full Text] [Related]
10. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Ravandi F; Döhner H; Wei AH; Montesinos P; Pfeilstöcker M; Papayannidis C; Lai Y; Wang K; See WL; de Menezes DL; Petrlik E; Prebet T; Roboz GJ
Br J Haematol; 2024 Mar; 204(3):877-886. PubMed ID: 37952982
[TBL] [Abstract] [Full Text] [Related]
11. Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia.
Shakah H; Tbakhi A; Khudirat S; Abweh RA; Hasasna N; Alwhaidi A; Khoujah A; Barakat F
J Int Med Res; 2023 Oct; 51(10):3000605231203842. PubMed ID: 37818740
[TBL] [Abstract] [Full Text] [Related]
12. [Clinical features and prognosis of core binding factor acute myeloid leukemia children in South China: a multicenter study].
Guo BY; Wang Y; Li J; Li CF; Feng XQ; Zheng MC; Liu SX; Yang LH; Jiang H; Xu HG; He XL; Wen H
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):881-888. PubMed ID: 37803854
[No Abstract] [Full Text] [Related]
13. Chimeric kinase alk induces expression of NAMPT and selectively depends on this metabolic enzyme to sustain its own oncogenic function.
Zhang Q; Basappa J; Wang HY; Nunez-Cruz S; Lobello C; Wang S; Liu X; Chekol S; Guo L; Ziober A; Nejati R; Shestov A; Feldman M; Glickson JD; Turner SD; Blair IA; Van Dang C; Wasik MA
Leukemia; 2023 Dec; 37(12):2436-2447. PubMed ID: 37773266
[TBL] [Abstract] [Full Text] [Related]
14. COVID-19 in patients with classic and variant hairy cell leukemia.
Kreitman RJ; Yu T; James L; Feurtado J; Eager H; Ortiz OS; Gould M; Mauter J; Zhou H; Burbelo PD; Cohen JI; Wang HW; Yuan CM; Arons E
Blood Adv; 2023 Dec; 7(23):7161-7168. PubMed ID: 37729613
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy of gilteritinib in comparison with alectinib for the treatment of alk-rearranged non-small cell lung cancer.
Ando C; Ichihara E; Nishi T; Morita A; Hara N; Takada K; Nakasuka T; Watanabe H; Kano H; Nishii K; Makimoto G; Kondo T; Ninomiya K; Fujii M; Kubo T; Ohashi K; Matsuoka KI; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2023 Nov; 114(11):4343-4354. PubMed ID: 37715310
[TBL] [Abstract] [Full Text] [Related]
16. Comparing presentations and outcomes of children with cancer: a study between a lower-middle-income country and a high-income country.
Farrag A; Ghazaly MH; Mohammed K; Volland R; Hero B; Berthold F
BMC Pediatr; 2023 Sep; 23(1):443. PubMed ID: 37670249
[TBL] [Abstract] [Full Text] [Related]
17. An interplay of Progesterone, leukemia Inhibitor Factor and Interleukin-6 in the window of implantation; Impact on fertility.
Ali R; Ahmed Khan T; Gul H; Rehman R
Cytokine; 2023 Oct; 170():156332. PubMed ID: 37586287
[TBL] [Abstract] [Full Text] [Related]
18. Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML).
Pohlmann A; Bentgens E; Schülke C; Kuron D; Reicherts C; Marx J; Angenendt L; Mikesch JH; Lenz G; Stelljes M; Schliemann C
Ann Hematol; 2023 Sep; 102(9):2543-2553. PubMed ID: 37428201
[TBL] [Abstract] [Full Text] [Related]
19. A Novel Fusion Partner, SP100, Drives Nuclear Dot Localization of alk in Epithelioid Fibrous Histiocytoma.
Russell-Goldman E; Dong F; Laga A; Hanna J
Am J Dermatopathol; 2023 Aug; 45(8):539-543. PubMed ID: 37377191
[TBL] [Abstract] [Full Text] [Related]
20. Exploring Prognostic Biomarkers of Acute Myeloid leukemia to Determine Its Most Effective Drugs from the FDA-Approved List through Molecular Docking and Dynamic Simulation.
Alom MM; Faruqe MO; Molla MKI; Rahman MM
Biomed Res Int; 2023; 2023():1946703. PubMed ID: 37359050
[TBL] [Abstract] [Full Text] [Related]
[Next]
